Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis

Barbara Delage(Smile Train), Peter W. Szlosarek(St Bartholomew's Hospital)

Cell Death and Disease

July 5, 2012

10.1038/cddis.2012.83

Cited by 151

Related Papers

Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

|Cancer Research|2011|60

Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers

|OncoImmunology|2021|44

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

|JTO Clinical and Research Reports|2020|30

A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma

|Pharmacological Reports|2023|5

Supplementary Figure 3 from Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer

|Unknown|2023|0